Abstract
Drugs are the critical elements in the health care system. They must be manufactured in the high-quality levels. End product testing by itself does not guarantee of the quality of the product. Quality assurance techniques must be used. In pharmaceutical industry, process validation performs this task, by ensuring that the process does what it purports to do. Validation is one of the important steps in achieving and maintaining the quality of the final product. If each step of production process is validated, we can assure that the final product is of the best quality. This study is intended to demonstrate and standardize the data that should be routinely included in the marketing authorization dossier describing evolution and validation of the manufacturing process and distinguish from the validation data which more properly fall under the remit of GMP inspection. During the study of critical process variables of sucralfate oral suspension were validated to demonstrate consistency of manufacturing process to produce the produce the product of desired quality. The validation studies were conducted which were intended for the use of commercial purpose so this validation study is concurrent type. All the in-process variables and finished product characteristics were monitored; the statistical analysis of data was carried out. Further from the results, it is inferred that the manufacturing process of sucralfate oral suspension was validated.
Full text article
References
Beckett, A. H., Stenlake, J. B. 1997. Practical Pharmaceutical Chemistry, 4th Ed, New Delhi. New Delhi. CBS. 275-325. ISBN-13:979-8123905135.
Desai, L., Oza, J., Khatri, K. 2012. Prospective process validation of polyherbal cough syrup formulation. Journal of Advanced Pharmacy Education, (4):225–231.
EMA 2012. Guideline on Process Validation (Draft), Geneva, Switzerland. pages 10–11. European Medicines Agency.
FDA 2011a. Guidance for industry, Process Validation: General Principles and Practice, Maryland, USA. United States Food and Drug Administration, pages 3–4.
FDA 2011b. Q8 guidelines for Pharmaceutical Development (Draft), Revision 1, version 8.1, Maryland. pages 2–3. United States Food and Drug Administration, USA.
ICH harmonized tripartite guideline 2009. Q8 Guidelines for Pharmaceutical Development, Revision 2, Geneva, Switzerland. pages 12–14. Inter- national conference on harmonisation of technical requirements for registration of pharmaceuticals for human use.
Levin, M. 2006. Pharmaceutical Process Scale-U. 2nd Edition. pages 199–220, New York. Taylor and Francis Group, CRC Press New York. ISBN: 10 #1- 57444-876-5.
Lloyd, R. S., Joseph, J. K., Joseph, L. G. 2007. Practical HPLC Method Development. 2nd Edition. pages 1–20, New York. Wiley-Interscience. ISBN: 978-0-471-00703-6.
Raveendranath, T. V., Kumar, K. K., Madhuri, L., Sasaikanth, K. 2010. Process validation of Citalopram Hydro bromide tablets. International Journal of Research in Pharmaceutical and Biomedical Sciences, 1(2):109–123.
Robert, A. N., Alfred, H. 2003. Pharmaceutical Process Validation. 3rd Edition, volume 129. pages 159–180, Marcel Dekker, New York. ISBN: 0-8247-0838-5.
Sethi, N. K., Hantus, S. 2016. Evaluating persistent altered mental status after status epilepticus Author Responds:. Neurology: Clinical Practice, 6:8.2–9.
Swarbrick, J., Boyan, J. C. 2002. Encyclopedia of Pharmaceutical Technology, 2nd Edition, Vol III. pages 2708–2709. Marcel Dekker Inc, New York. ISBN: 0-8247-2822-X.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.